FRONTLINE PLC (FRO)
(Real Time Quote from BATS)
$23.85 USD
+0.41 (1.75%)
Updated Apr 26, 2024 03:02 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
FRO 23.85 +0.41(1.75%)
Will FRO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FRO
These 2 Transportation Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Boost Your Portfolio with Top Transportation Stocks Set to Beat Earnings
FRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Frontline (FRO) Stock Moves -0.7%: What You Should Know
How to Boost Your Portfolio with Top Transportation Stocks Set to Beat Earnings
How to Boost Your Portfolio with Top Transportation Stocks Set to Beat Earnings
Other News for FRO
Frontline: How Geopolitical Shifts Are Steering Growth For Tanker Operations
June 21st Options Now Available For Frontline (FRO)
Kepler Capital Sticks to Its Buy Rating for Frontline (FRO)
3 Best Dividend Stocks to Buy in April 2024, According to Analysts
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday